Automated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamide.
Research output: Contribution to journal › Article
Having performed analytical validation studies, we are now assessing the clinical utility of the upgraded automated Bone Scan Index (BSI) in metastatic castration-resistant prostate cancer (mCRPC). In the present study, we retrospectively evaluated the discriminatory strength of the automated BSI in predicting overall survival (OS) in mCRPC patients being treated with enzalutamide.
|Research areas and keywords||
Subject classification (UKÄ) – MANDATORY
|Publication status||Published - 2016 Mar 9|
Related research output
Quantitative Imaging-Biomarker in Prostate Cancer. Validation of Automated Bone Scan Index in the Context of Radiographic Disease Progression in Metastatic Castration Resistant Prostate CancerAseem Undvall Anand, 2017, Lund: Aseem Undvall Anand. 55 p.
Research output: Thesis › Doctoral Thesis (compilation)